



[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel
FEB2020 Cycle 34 NEXt SEP Committee Meeting

Date: April 21, 2020

Time: 9:00 AM to 3:00 PM

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.

Place: National Institutes of Health
9000 Rockville Pike
Building 31, Room 3A44
Bethesda, MD 20892
Teleconference Call

Contact Persons: Barbara Mroczkowski, Ph.D.
Executive Secretary
Discovery Experimental Therapeutics Program
National Cancer Institute, NIH
31 Center Drive, Room 3A44
Bethesda, MD 20817
(301) 496-4291
mroczkoskib@mail.nih.gov

Toby Hecht, Ph.D.
Executive Secretary
Development Experimental Therapeutics Program
National Cancer Institute, NIH
9609 Medical Center Drive, Room 3W110
Rockville, MD 20850
(240) 276-5683
toby.hecht2@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 16, 2020

Melanie J. Pantoja, Program Analyst
Office of Federal Advisory Committee Policy
[FR Doc. 2020-05817 Filed: 3/19/2020 8:45 am; Publication Date: 3/20/2020]